Cargando…

Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management

Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaebler, Manuela, Silvestri, Alessandra, Haybaeck, Johannes, Reichardt, Peter, Lowery, Caitlin D., Stancato, Louis F., Zybarth, Gabriele, Regenbrecht, Christian R. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601986/
https://www.ncbi.nlm.nih.gov/pubmed/28955656
http://dx.doi.org/10.3389/fonc.2017.00203
_version_ 1783264499597312000
author Gaebler, Manuela
Silvestri, Alessandra
Haybaeck, Johannes
Reichardt, Peter
Lowery, Caitlin D.
Stancato, Louis F.
Zybarth, Gabriele
Regenbrecht, Christian R. A.
author_facet Gaebler, Manuela
Silvestri, Alessandra
Haybaeck, Johannes
Reichardt, Peter
Lowery, Caitlin D.
Stancato, Louis F.
Zybarth, Gabriele
Regenbrecht, Christian R. A.
author_sort Gaebler, Manuela
collection PubMed
description Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant neoplasms originating from mesenchymal cells, for which the main therapeutic approach still consists in the combination of surgery, chemotherapy, and radiation therapy. The lack of innovative approaches in sarcoma treatment stems from the high degree of heterogeneity of this tumor type, with more that 70 different histopathological subtypes, and the limited knowledge of the molecular drivers of tumor development and progression. Currently, molecular therapies are available mainly for the treatment of gastrointestinal stromal tumor, a soft-tissue malignancy characterized by an activating mutation of the tyrosine kinase KIT. Since the first application of this approach, a strong effort has been made to understand sarcoma molecular alterations that can be potential targets for therapy. The low incidence combined with the high level of histopathological heterogeneity makes the development of clinical trials for sarcomas very challenging. For this reason, preclinical studies are needed to better understand tumor biology with the aim to develop new targeted therapeutics. Currently, these studies are mainly based on in vitro testing, since cell lines, and in particular patient-derived models, represent a reliable and easy to handle tool for investigation. In the present review, we summarize the most important models currently available in the field, focusing in particular on the three-dimensional spheroid/organoid model. This innovative approach for studying tumor biology better represents tissue architecture and cell–cell as well as cell–microenvironment crosstalk, which are fundamental steps for tumor cell proliferation and survival.
format Online
Article
Text
id pubmed-5601986
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56019862017-09-27 Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management Gaebler, Manuela Silvestri, Alessandra Haybaeck, Johannes Reichardt, Peter Lowery, Caitlin D. Stancato, Louis F. Zybarth, Gabriele Regenbrecht, Christian R. A. Front Oncol Oncology Over the past decade, the development of new targeted therapeutics directed against specific molecular pathways involved in tumor cell proliferation and survival has allowed an essential improvement in carcinoma treatment. Unfortunately, the scenario is different for sarcomas, a group of malignant neoplasms originating from mesenchymal cells, for which the main therapeutic approach still consists in the combination of surgery, chemotherapy, and radiation therapy. The lack of innovative approaches in sarcoma treatment stems from the high degree of heterogeneity of this tumor type, with more that 70 different histopathological subtypes, and the limited knowledge of the molecular drivers of tumor development and progression. Currently, molecular therapies are available mainly for the treatment of gastrointestinal stromal tumor, a soft-tissue malignancy characterized by an activating mutation of the tyrosine kinase KIT. Since the first application of this approach, a strong effort has been made to understand sarcoma molecular alterations that can be potential targets for therapy. The low incidence combined with the high level of histopathological heterogeneity makes the development of clinical trials for sarcomas very challenging. For this reason, preclinical studies are needed to better understand tumor biology with the aim to develop new targeted therapeutics. Currently, these studies are mainly based on in vitro testing, since cell lines, and in particular patient-derived models, represent a reliable and easy to handle tool for investigation. In the present review, we summarize the most important models currently available in the field, focusing in particular on the three-dimensional spheroid/organoid model. This innovative approach for studying tumor biology better represents tissue architecture and cell–cell as well as cell–microenvironment crosstalk, which are fundamental steps for tumor cell proliferation and survival. Frontiers Media S.A. 2017-09-11 /pmc/articles/PMC5601986/ /pubmed/28955656 http://dx.doi.org/10.3389/fonc.2017.00203 Text en Copyright © 2017 Gaebler, Silvestri, Haybaeck, Reichardt, Lowery, Stancato, Zybarth and Regenbrecht. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gaebler, Manuela
Silvestri, Alessandra
Haybaeck, Johannes
Reichardt, Peter
Lowery, Caitlin D.
Stancato, Louis F.
Zybarth, Gabriele
Regenbrecht, Christian R. A.
Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title_full Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title_fullStr Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title_full_unstemmed Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title_short Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
title_sort three-dimensional patient-derived in vitro sarcoma models: promising tools for improving clinical tumor management
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601986/
https://www.ncbi.nlm.nih.gov/pubmed/28955656
http://dx.doi.org/10.3389/fonc.2017.00203
work_keys_str_mv AT gaeblermanuela threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT silvestrialessandra threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT haybaeckjohannes threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT reichardtpeter threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT lowerycaitlind threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT stancatolouisf threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT zybarthgabriele threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement
AT regenbrechtchristianra threedimensionalpatientderivedinvitrosarcomamodelspromisingtoolsforimprovingclinicaltumormanagement